The FDA has approved Orzeyful (oveporexton), a first-in-class oral orexin receptor 2 agonist, for the treatment of adult narcolepsy type 1.

Narcolepsy is a neurological disorder that interferes with the brain’s ability to control sleep-wake cycles. This lifelong condition can have serious negative effects on physical, psychological, ...

As Takeda’s oveporexton (Orzeyful) becomes a first-in-class treatment for narcolepsy type 1, industry eyes broader indications for orexin receptor agonists. The FDA has approved Takeda’s oveporexton ...

We conducted a phase 2, randomized, placebo-controlled trial of TAK-994, an oral orexin receptor 2–selective agonist, in patients with narcolepsy type 1. Patients with confirmed narcolepsy type 1 ...

A new Northwestern Medicine study has demonstrated a new way to treat narcolepsy-related nightmares. The scientists combined cognitive behavioral therapy (CBT) and lucid dreaming to help patients in a ...

Narcolepsy and idiopathic hypersomnia (IH) both lead to daytime sleepiness, fatigue, and brain fog. Narcolepsy can involve muscle weakness and sleep paralysis, while IH may lead to non-refreshing ...